Oxford Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Oxford Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,664	Closed	-$524K	–	599
2026 Q1	$524K	Buy	15,664 +643	+4%	+$25.2K	0.21%	148
2025 Q4	$695K	Buy	+15,021	New	+$824K	0.25%	132

Oxford Asset Management's SLNO Position: Q2 2026 in Review

Oxford Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 15,664 shares — an estimated $524K sold.

Oxford Asset Management first reported a position in SLNO in Q4 2025 and held it in 2 quarters. The position peaked at $695K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Oxford Asset Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Oxford Asset Management sold 15,664 Soleno Therapeutics shares in Q2 2026, an estimated $524K.
Oxford Asset Management first reported a position in Soleno Therapeutics in Q4 2025 and held it in 2 quarters.
Oxford Asset Management's Soleno Therapeutics position peaked at $695K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.